You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 7, July 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Letters to the Editor
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Drug Therapy, Other
 •Substance Abuse/ Alcoholism
 •Statistics and Research Methods
 •Psychopharmacology
 •Drug Therapy
 •Public Health
 •Alert me on articles by topic

Lack of Information in Naltrexone Study

Darius A. Rastegar, MD

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Comer and colleagues1 have shown that an injectable, sustained-release formulation of naltrexone can be effective for the treatment of opioid dependence in selected individuals. While these findings are promising, the impact of this treatment option will likely be limited by low rates of patient acceptance.2 Unfortunately, the authors have given us a long list of exclusion criteria but do not provide any data on the number of heroin-dependent men and women who were screened to recruit the 60 subjects in their study. Furthermore, it appears that they used a run-in period during which all subjects received naltrexone to see whether "they were willing and able to tolerate the effects of depot naltrexone"; it would be very helpful if the authors reported how many subjects dropped out during this phase of the trial. I am surprised that the Archives did not adhere to the CONSORT guidelines3 (which . . . [Full Text of this Article]


AUTHOR INFORMATION

RELATED LETTER

Lack of Information in Naltrexone Study—Reply
Sandra D. Comer, Maria A. Sullivan, Elmer Yu, Jami L. Rothenberg, Herbert D. Kleber, Kyle Kampman, Charles Dackis, and Charles P. O’Brien
Arch Gen Psychiatry. 2007;64(7):865.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Injectable, Sustained-Release Naltrexone for the Treatment of Opioid Dependence: A Randomized, Placebo-Controlled Trial
Sandra D. Comer, Maria A. Sullivan, Elmer Yu, Jami L. Rothenberg, Herbert D. Kleber, Kyle Kampman, Charles Dackis, and Charles P. O’Brien
Arch Gen Psychiatry. 2006;63(2):210-218.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.